RESUMO
The association of two pharmacophoric entities generates so-called 'twin drugs' or dimer derivatives. We applied this approach for the design of a small compound library for the interaction with α4ß2(∗) nicotinic acetylcholine receptors (nAChRs). In this compound series, the nAChR ligand N,N-dimethyl-2-(pyridin-3-yloxy)ethan-1-amine 9 served as one pharmacological entity and it was initially kept constant as one part of the 'twin' compound. 'Twin' compounds with identical or non-identical entities using the 'no linker mode' or 'overlap' mode were synthesized and evaluated for their nAChR affinities. Compound 17a showed the highest affinity for the α4ß2(∗) nAChR subtype (Ki=0.188 nM) and its (di)fluoro analogs could retain nanomolar affinities, when replacing pyridine as the hydrogen bond acceptor system by mono- or difluoro-phenyls. The 'twin drug' approach proved to provide compounds with high affinity and subtype selectivity for α4ß2(∗) nAChRs.
Assuntos
Agonistas Nicotínicos/química , Receptores Nicotínicos/química , Animais , Dimerização , Desenho de Fármacos , Ligantes , Camundongos , Agonistas Nicotínicos/síntese química , Relação Quantitativa Estrutura-Atividade , Receptores Nicotínicos/metabolismoRESUMO
Design, synthesis and evaluation of new acetylcholinesterase inhibitors by combining quinolinecarboxamide to a benzylpiperidine moiety are described. Then, a series of hybrids have been developed by introducing radical scavengers. Molecular modeling was performed and structure activity relationships are discussed. Among the series, most potent compounds show effective AchE inhibitions, high selectivities over butyrylcholinesterase and high radical scavenging activities. On the basis of this work, the ability of quinolone derivatives to serve in the design of N-benzylpiperidine linked multipotent molecules for the treatment of Alzheimer Disease has been established.
Assuntos
Acetilcolinesterase/química , Antioxidantes/química , Inibidores da Colinesterase/química , Piperidinas/química , Quinolonas/química , Acetilcolinesterase/metabolismo , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/enzimologia , Doença de Alzheimer/patologia , Antioxidantes/metabolismo , Sítios de Ligação , Domínio Catalítico , Inibidores da Colinesterase/síntese química , Inibidores da Colinesterase/metabolismo , Inibidores da Colinesterase/uso terapêutico , Humanos , Simulação de Acoplamento Molecular , Piperidinas/uso terapêutico , Relação Estrutura-AtividadeRESUMO
Partial agonist therapies for the treatment of nicotine addiction and dependence depend on both agonistic and antagonistic effects of the ligands, and side effects associated with other nAChRs greatly limit the efficacy of nicotinic partial agonists. We evaluated the in vitro pharmacological properties of four partial agonists, two current smoking cessation drugs, varenicline and cytisine, and two novel bispidine compounds, BPC and BMSP, by using defined nAChR subtypes expressed in Xenopus laevis oocytes and human embryonic kidney 293 cells. Similar to varenicline and cytisine, BPC and BMSP are partial agonists of α4ß2 nAChRs, although BMSP produced very little activation of these receptors. Unlike varenicline and cytisine, BPC and BMSP showed desired low activity. BPC produced mecamylamine-sensitive steady-state activation of α4* receptors that was not evident with BMSP. We evaluated the modulation of α4*- and α7-mediated responses in rat lateral geniculate nucleus (LGN) neurons and hippocampal stratum radiatum (SR) interneurons, respectively. The LGN neurons were sensitive to a very low concentration of varenicline, and the SR interneuron responses were also sensitive to varenicline at a submicromolar concentration. Although 300 nM BPC strongly inhibited the ACh-evoked responses of LGN neurons, it did not inhibit the α7 currents of SR interneurons. Similar results were observed with 300 nM BMSP. Additionally, the bispidine compounds were efficacious in the mouse tail suspension test, demonstrating that they affect receptors in the brain when delivered systemically. Our data indicate that BPC and BMSP are promising α4ß2* partial agonists for pharmacotherapeutics.
Assuntos
Alcaloides/farmacologia , Benzazepinas/farmacologia , Encéfalo/efeitos dos fármacos , Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia , Agonistas Nicotínicos/farmacologia , Quinoxalinas/farmacologia , Receptores Nicotínicos/metabolismo , Alcaloides/química , Animais , Azocinas/química , Azocinas/farmacologia , Comportamento Animal/efeitos dos fármacos , Benzazepinas/química , Encéfalo/metabolismo , Compostos Bicíclicos Heterocíclicos com Pontes/química , Relação Dose-Resposta a Droga , Agonismo Parcial de Drogas , Células HEK293 , Humanos , Masculino , Potenciais da Membrana/efeitos dos fármacos , Camundongos , Estrutura Molecular , Agonistas Nicotínicos/química , Oócitos/metabolismo , Técnicas de Patch-Clamp , Quinolizinas/química , Quinolizinas/farmacologia , Quinoxalinas/química , Ratos , Ratos Sprague-Dawley , Receptores Nicotínicos/genética , Tabagismo/tratamento farmacológico , Tabagismo/metabolismo , Tabagismo/psicologia , Vareniclina , Xenopus laevisRESUMO
3,7-Diazabicyclo[3.3.1]nonane (bispidine) based nicotinic acetylcholine receptor (nAChR) ligands have been synthesized and evaluated for nAChRs interaction. Diverse spacer motifs were incorporated between the hydrogen bond acceptor (HBA) part and a variety of substituted (hetero)aryl moieties. Bispidine carboxamides bearing spacer motifs often showed high affinity in the low nanomolar range and selectivity for the α4ß2(∗) nAChR. Compounds 15, 25, and 47 with Ki values of about 1 nM displayed the highest affinities for α4ß2(∗) nAChR. All evaluated compounds are partial agonists or antagonists at α4ß2(∗), with reduced or no effects on α3ß4(∗) with the exception of compound 15 (agonist), and reduced or no effect at α7 and muscle subtypes.
Assuntos
Alcanos/química , Compostos Bicíclicos Heterocíclicos com Pontes/química , Agonistas Nicotínicos/química , Antagonistas Nicotínicos/química , Receptores Nicotínicos/metabolismo , Alcanos/farmacologia , Animais , Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia , Camundongos , Agonistas Nicotínicos/farmacologia , Antagonistas Nicotínicos/farmacologia , Receptores Nicotínicos/química , Relação Estrutura-AtividadeRESUMO
3,7-Diazabicyclo[3.3.1]nonane is a naturally occurring scaffold interacting with nicotinic acetylcholine receptors (nAChRs). When one nitrogen of the 3,7-diazabicyclo[3.3.1]nonane scaffold was implemented in a carboxamide motif displaying a hydrogen bond acceptor (HBA) functionality, compounds with higher affinities and subtype selectivity for α4ß2(∗) were obtained. The nature of the HBA system (carboxamide, sulfonamide, urea) had a strong impact on nAChR interaction. High affinity ligands for α4ß2(∗) possessed small alkyl chains, small un-substituted hetero-aryl groups or para-substituted phenyl ring systems along with a carboxamide group. Electrophysiological responses of selected 3,7-diazabicyclo[3.3.1]nonane derivatives to Xenopus oocytes expressing various nAChR subtypes showed diverse activation profiles. Compounds with strongest agonistic profiles were obtained with small alkyl groups whereas a shift to partial agonism/antagonism was observed for aryl substituents.
Assuntos
Alcanos/química , Compostos Bicíclicos com Pontes/química , Agonistas Nicotínicos/química , Antagonistas Nicotínicos/química , Receptores Nicotínicos/metabolismo , Alcanos/farmacologia , Animais , Compostos Bicíclicos com Pontes/farmacologia , Bovinos , Linhagem Celular , Ligação de Hidrogênio , Ligantes , Camundongos , Agonistas Nicotínicos/farmacologia , Antagonistas Nicotínicos/farmacologia , Ratos , Receptores Nicotínicos/química , Relação Estrutura-Atividade , Torpedo , XenopusRESUMO
Thediazabicyclic molecule bispidine named by the chemist Carl Mannich in 1930, is a naturally occurring scaffold with interesting features. Bispidine can form different conformers, has high basicity, can attack dichloromethane, has metal ion coordination properties and interacts with nicotinic acetylcholine receptors. In this review we will discuss important properties, synthetic pathways and biological activities of bispidine and some derivatives. Bispidine can function as a scaffold for compounds with very diverse biological activities, e.g. interacting with ion channels, G-protein coupled receptors, and enzymes, and is even used for the development of new in vivo radiotracers.
Assuntos
Anti-Infecciosos/farmacologia , Antineoplásicos/farmacologia , Compostos Bicíclicos Heterocíclicos com Pontes/química , Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia , Inibidores da Agregação Plaquetária/farmacologia , Ensaio Radioligante , Anti-Infecciosos/química , Antídotos/química , Antídotos/farmacologia , Antineoplásicos/química , Humanos , Canais Iônicos/química , Canais Iônicos/metabolismo , Neoplasias/diagnóstico , Neoplasias/tratamento farmacológico , Inibidores da Agregação Plaquetária/química , Receptores de Superfície Celular/química , Receptores de Superfície Celular/metabolismoRESUMO
From well-known antioxidants agents, we developed a first pharmacophore model containing four common chemical features: one aromatic ring and three hydrogen bond acceptors. This model served as a template in virtual screening of Maybridge and NCI databases that resulted in selection of sixteen compounds. The selected compounds showed a good antioxidant activity measured by three chemical tests: DPPH radical, OH° radical, and superoxide radical scavenging. New synthetic compounds with a good correlation with the model were prepared, and some of them presented a good antioxidant activity.
RESUMO
The synthesis, biological evaluation, and molecular modeling of new 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamides(4), 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbohydrazide (6), and some hexahydropyrimido[5,4-c]quinoline-2,5-diones (9) produced earlier by our laboratory, as AChE/BuChE inhibitors, is described. From these analyses compound 4c resulted equipotent regarding the inhibition of cholinesterases'; inhibitors 6k, 9a, 9b were selective for AChE, whereas product 4d proved selective for BuChE. Docking analysis has been carry out in order to identify the binding mode in the active site, and to explain the observed selectivities. Only compound 9a has been shown to decrease K(+)-induced calcium signals in bovine chromaffin cells.